Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the effectiveness of two dose levels of ONTAK
(denileukin diftitox) in treating patients who have recurrent or persistent cutaneous T-cell
lymphoma.